Provectus Pharmaceuticals Inc is certainly a company to watch very closely in the years ahead
CEOCFOinterviews: What would you like to say to potential investors?
Dr. Dees: "They approach us once they get a good look at our analysis of the net worth of our properties. We have a tremendously deep patent portfolio and its growing. We have thirteen issued patents and a number of allowances as well as nineteen or twenty more in the pipe in the process. We are deep in property. We had to do a survey of the things we had on the books. Our external auditor had us prove it to them. We had it booked at that time for $20.5 million. We did a very conservative analysis of the business. We did not even put in any OTC. We did one cancer, psoriasis, and we came up with the number of $406 million. That was before multiple more patents had been issued and before we got the new IND. That is now obsolete. If you look at our number of shares outstanding which is only 36.7 million, and divide it into 400-600 million, you immediately see that we are one of the most undervalued stocks out there."
PVCT 6 months chart:
stockcharts.com
Technical analysis:
stockta.com
Price targets according to the investors(May 07,2006)
USERS CONSENSUS FORECAST
May 09,2006
Last Close: 1.97
1 week: 2.43 23.3% 0.42 0.18
1 month: 3.2 62.4% 0.58 0.09
3 months: 3.35 70% 0.39 0.72
6 months: 4.94 150.7% 1.34 1.12
12 months: 8.95 354.3% 3.07 3.47
stocktargets.com
Provectus Pharmaceuticals, Inc., a development-stage biopharmaceutical company, engages in the development, licensing, and marketing of over-the-counter (OTC) products, prescription drugs, and medical device systems. The company offers prescription drug products for the invasive treatment of chronic severe skin afflictions, such as psoriasis, eczema, and acne; and liver, breast, and prostate cancer. Its OTC products address markets primarily involving skincare applications, including hand irritation associated with use of disposable gloves, eczema, psoriasis, and mild to moderate acne. The company is also developing medical devices for cosmetic treatments, such as reduction of wrinkles and elimination of spider veins and other cosmetic blemishes, as well as for therapeutic uses, including photoactivation of its prescription drugs and nonsurgical destruction of certain skin cancers. Provectus Pharmaceuticals is based in Knoxville, Tennessee.
The Company's offices and laboratory are located at 7327 Oak Ridge Highway, Suite A, Knoxville, TN 37931; telephone: 865-769-4011. For more information, contact the Company at info@pvct.com or visit the corporate Web site: pvct.com .
PVCT News:
finance.yahoo.com
CEO INTERVIEW
-------------------------
July 25, 2005
wallst.net
february 2005
ceocfointerviews.com
financialnewsusa.com
macreport.net
May 16,2006
webcast presentation at the Rodman & Renshaw Global Healthcare Conference
wsw.com
PVCT profiled by Allen&Caron Inc.(May 2006)
allencaron.com
PVCT Video CNBC Europe interview with CEO Craig Dees, Ph.D.
Decembre 23,2005
pvct.com
PVCT on its way to Fast Track FDA Approval:
knoxnews.com
DETAILED RESEARCH REPORTS:
-----------------------------------------------------
December 12,2005
pvct.com
June 2005
pvct.com
May 4, 2006 Dutton Associates start PVCT coverage
jmdutton.com
jmdutton.com
--------------------------------------------------------------
PVCT insiders transactions:
secform4.com
--------------------------------------------------------------
Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.
pvct.com |
